Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alkermes Schizophrenia Drug Aristada Wins FDA Nod

This article was originally published in Scrip

Executive Summary

After the U.S. markets closed on Oct. 5, Alkermes plc revealed it had gained the FDA's approval to market Aristada (aripiprazole lauroxil) extended-release injectable suspension as a treatment for schizophrenia.



Related Companies